Several brokerages have updated their recommendations and price targets on shares of Asterias Biotherapeutics (NYSEMKT: AST) in the last few weeks:

  • 9/19/2016 – Asterias Biotherapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
  • 9/14/2016 – Asterias Biotherapeutics had its “buy” rating reaffirmed by analysts at FBR & Co.
  • 9/11/2016 – Asterias Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 8/31/2016 – Asterias Biotherapeutics had its “buy” rating reaffirmed by analysts at FBR & Co.
  • 8/18/2016 – Asterias Biotherapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.25 price target on the stock. According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Shares of Asterias Biotherapeutics Inc. (NYSEMKT:AST) traded down 1.58% during midday trading on Tuesday, hitting $4.35. The company had a trading volume of 714,583 shares. The stock’s market capitalization is $197.57 million. The stock’s 50-day moving average price is $3.13 and its 200-day moving average price is $3.57. Asterias Biotherapeutics Inc. has a one year low of $2.30 and a one year high of $6.10.

Asterias Biotherapeutics (NYSEMKT:AST) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.07. The business earned $1.53 million during the quarter, compared to analysts’ expectations of $1.14 million. Analysts predict that Asterias Biotherapeutics Inc. will post ($0.73) EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/investment-analysts-recent-ratings-updates-for-asterias-biotherapeutics-ast.html

In other news, COO Katharine E. Spink sold 19,336 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $3.52, for a total value of $68,062.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Edward Wirth sold 14,760 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $3.52, for a total transaction of $51,955.20. The disclosure for this sale can be found here.

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.